-
Article
Open AccessConditional survival to assess prognosis in patients with chronic lymphocytic leukemia
Biomarkers in chronic lymphocytic leukemia (CLL) allow assessment of prognosis. However, the validity of current prognostic biomarkers based on a single assessment point remains unclear for patients who have s...
-
Article
Karzinom unklaren Ursprungs – interdisziplinäre Therapiestruktur
Das Karzinom unklaren Ursprungs (CUP) stellt nach wie vor eine diagnostische und therapeutische Herausforderung dar. Die Prognose dieser Tumorerkrankung ist für den überwiegenden Teil der Patienten, nämlich di...
-
Article
NGS-basierte Molekulargenetik der Leukämie – ein leistungsfähiger und dezentraler Lösungsansatz
Die Diagnostik der akuten myeloischen Leukämie (AML) und des myelodysplastischen Syndroms (MDS), die ursprünglich primär auf einer morphologischen Beurteilung beruhte, integriert nun immer mehr unterschiedlich...
-
Article
Open AccessPredictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from trea...
-
Article
Open AccessSarcoidosis mimicking nodal manifestations of marginal zone lymphoma
-
Article
Open AccessAlterations of circulating lymphocyte subsets in patients with colorectal carcinoma
Cellular immune response to cancer is known to be of great importance for tumor control. Moreover, solid tumors influence circulating lymphocytes, which has been shown for several types of cancer. In our prosp...
-
Article
Open AccessBisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction
Single-cell multi-omics are powerful means to study cell-to-cell heterogeneity. Here, we present a single-tube, bisulfite-free method for the simultaneous, genome-wide analysis of DNA methylation and genetic v...
-
Article
Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning—a matched pair analysis
In acute myeloid leukemia (AML), primary refractory or relapsed disease, secondary AML, and leukemia with unfavorable genetics are considered high-risk AML (hrAML), with allogeneic stem cell transplantation (S...
-
Article
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal evolution likely has therapeutic implications but its dyna...
-
Article
Open AccessAvelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC).
-
Article
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nat. Med. 24, 282–291 (2018); published online 12 February 2018; corrected after print 6 March 2018 In the version of this article initially published, Omid Shah's name was misspelled as Omid Sha. The error ha...
-
Article
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Combining the kinase inhibitor sorafenib with allogeneic stem cell transplantation boosts immune responses against a subtype of acute myelogenous leukemia, suggesting potential clinical benefit.
-
Article
Open AccessRAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood characterized by mutations activating RAS signaling. Established clinical and genetic markers fail to ful...
-
Article
Open AccessPRC2 inhibition counteracts the culture-associated loss of engraftment potential of human cord blood-derived hematopoietic stem and progenitor cells
Cord blood hematopoietic stem cells (CB-HSCs) are an outstanding source for transplantation approaches. However, the amount of cells per donor is limited and culture expansion of CB-HSCs is accompanied by a lo...
-
Article
Open AccessEarly aberrant DNA methylation events in a mouse model of acute myeloid leukemia
Aberrant DNA methylation is frequently found in human malignancies including acute myeloid leukemia (AML). While most studies focus on later disease stages, the onset of aberrant DNA methylation events and the...
-
Article
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer
Tumour genomes are characterized by extensive alterations that affect the genome as well as the epigenome. Both types of alterations change global gene express...
-
Article
Open AccessPromoter DNA methylation regulates progranulin expression and is altered in FTLD
Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of neurodegenerative diseases associated with personality changes and progressive dementia. Loss-of-function mutations in the growth factor pro...
-
Article
Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC)
AMP-activated protein kinase (AMPK) is an energy sensing/signalling intracellular protein which is activated by an increase in the cellular AMP:ATP ratio after ATP depletion. Once activated, AMPK inhibits fatt...
-
Chapter
Genome-Wide Epigenetic Modifications in Cancer
Epigenetic alterations in cancer include changes in DNA methylation and associated histone modifications that influence the chromatin states and impact gene expression patterns. Due to recent technological adv...
-
Article
Epigenetic targets in hematopoietic malignancies
Frequent genetic alterations in hematopoietic neoplasias (chromosomal translocations, point mutations, etc.) have provided biologic targets for the development of effective novel therapies. A rapidly increasin...
